Advertisement

Tumor Biology

, Volume 34, Issue 1, pp 125–130 | Cite as

Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand

  • Eirini Taliouri
  • Thomas Vrekoussis
  • Aikaterini Vergetaki
  • Theodore Agorastos
  • Antonis Makrigiannakis
Research Article

Abstract

Corticotropin-releasing hormone acts as a stressor mediator in the human reproductive system. Corticotropin-releasing hormone (CRH) has been detected in several carcinomas of gynecological origin like breast, ovarian, and endometrial carcinomas. It was additionally shown that CRH could induce Fas ligand (FasL) expression in ovarian carcinoma cell lines. To determine whether CRH could also be expressed during cervical cancer development, we studied the expression of CRH using HeLa cells in an in vitro cervical cancer model. We further studied whether CRH could regulate FasL expression. In that context, HeLa cells were cultured in the presence or absence of 1 μM CRH. CRH and FasL expressions were assessed by indirect immunofluorescence, reverse transcription PCR, and Western blot. The current results indicated that in HeLa cells, CRH can significantly induce both FasL transcription and FasL translation. Taking into account previous studies already establishing a connection between FasL expression and tumor immunoescape in cervical cancer, it can be concluded that such immunoescape could be CRH dependent.

Keywords

Cervical cancer cell line HeLa Expresses CRH 

Abbreviations

CRH

Corticotropin-releasing hormone

HPA

Hypothalamic–pituitary–adrenal

FasL

Fas ligand

HeLa

Human cervical carcinoma cell line

HPV

Human papillomavirus

PCR

Polymerase chain reaction

DMEM

Dulbecco’s modified Eagle medium

FBS

Fetal bovine serum

PBS

Phosphate-buffered saline

HAS

Human serum albumin

M-PER

Mammalian protein extraction reagent

rt

Room temperature

mcg

Micrograms

CNS

Central nervous system

FIGO

International Federation of Gynecology and Obstetrics

Notes

Acknowledgments

The authors would like to thank Agapi Stamataki and Eirini Neofytou for their technical assistance.

Conflicts of interest

None

References

  1. 1.
    Kalantaridou SN, Zoumakis E, Makrigiannakis A, et al. Corticotropin-releasing hormone, stress and human reproduction: an update. J Reprod Immunol. 2010;85:33–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Bonfiglio JJ, Inda C, Refojo D, et al. The corticotropin-releasing hormone network and the hypothalamic-pituitary-adrenal axis: molecular and cellular mechanisms involved. Neuroendocrinology. 2011;94:12–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Kalantaridou SN, Makrigiannakis A, Zoumakis E, Chrousos GP. Stress and the female reproductive system. J Reprod Immunol. 2004;62(1–2):61–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Kalantaridou SN, Makrigiannakis A, Mastorakos G, Chrousos GP. Roles of reproductive corticotropin-releasing hormone. Ann N Y Acad Sci. 2003;997:129–35.PubMedCrossRefGoogle Scholar
  5. 5.
    Bartek J, Mistrik M, Bartkova J. Thresholds of replication stress signaling in cancer development and treatment. Nat Struct Mol Biol. 2012;19(1):5–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Walker PR, Saas P, Dietrich PY, et al. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol. 1997;158:4521–4.PubMedGoogle Scholar
  7. 7.
    Ciocca DR, Puy LA, Fasoli LC, et al. Corticotropin-releasing hormone, luteinizing hormone releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat. 1990;15:175–84.PubMedCrossRefGoogle Scholar
  8. 8.
    Miceli F, Ranelletti FO, Martinelli E, et al. Expression and subcellular localization of CRH and its receptors in human endometrial cancer. Mol Cell Endocrinol. 2009;305:6–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Minas V, Rolaki A, Kalantaridou SN, et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer. 2007;97:637–45.PubMedCrossRefGoogle Scholar
  10. 10.
    Makrigiannakis A, Zoumakis E, Kalantaridou S, et al. Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nat Immunol. 2001;2:1018–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Ehrenschwender M, Wajant H. The role of FasL and Fas in health and disease. Adv Exp Med Biol. 2009;647:64–93.PubMedCrossRefGoogle Scholar
  12. 12.
    Mountz JD, Zhou T, Bluethmann H, et al. Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice. Int Rev Immunol. 1994;11:321–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Lettau M, Paulsen M, Schmidt H, et al. Insights into the molecular regulation of FasL (CD178) biology. Eur J Cell Biol. 2010;90:456–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Grino M, Chrousos GP, Margioris AN. The corticotropin releasing hormone gene is expressed in human placenta. Biochem Biophys Res Commun. 1987;148(3):1208–14.PubMedCrossRefGoogle Scholar
  15. 15.
    Kalantaridou S, Makrigiannakis A, Zoumakis E, et al. Peripheral corticotropin-releasing hormone is produced in the immune and reproductive systems: actions, potential roles and clinical implications. Front Biosci. 2007;12:572–80.PubMedCrossRefGoogle Scholar
  16. 16.
    Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5:374–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71(6):907–20.PubMedGoogle Scholar
  19. 19.
    Kim R, Emi M, Tanabe K, et al. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004;100(11):2281–91.PubMedCrossRefGoogle Scholar
  20. 20.
    Okada K, Komuta K, Hashimoto S, et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res. 2000;6:3560–4.PubMedGoogle Scholar
  21. 21.
    Mottolese M, Buglioni S, Bracalenti C, et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer. 2000;89:127–32.PubMedCrossRefGoogle Scholar
  22. 22.
    Ito Y, Monden M, Takeda T, et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer. 2000;82:1211–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997;57:1007–12.PubMedGoogle Scholar
  24. 24.
    Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest. 1997;99:1173–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Shibakita M, Tachibana M, Dhar DK, et al. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res. 1999;5:2464–9.PubMedGoogle Scholar
  26. 26.
    Kim YS, Kim KH, Choi JA, et al. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors. Arch Pathol Lab Med. 2000;124:687–93.PubMedGoogle Scholar
  27. 27.
    Munakata S, Enomoto T, Tsujimoto M, et al. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer. 2000;82:1446–52.PubMedCrossRefGoogle Scholar
  28. 28.
    Ibrahim R, Frederickson H, Parr A, et al. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer. 2006;106:1065–77.PubMedCrossRefGoogle Scholar
  29. 29.
    Reesink-Peters N, Hougardy BM, van den Heuvel FA, et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol. 2005;96:705–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Zhou JH, Chen HZ, Ye F, et al. Fas-mediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncol Rep. 2006;16:307–11.PubMedGoogle Scholar
  31. 31.
    Münger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Stanley MA. Immune responses to human papilloma viruses. Indian J Med Res. 2009;130(3):266–76.PubMedGoogle Scholar
  33. 33.
    Cohen S, Janicki-Deverts D, Doyle WJ, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci U S A. 2012;109(16):5995–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Tay SK. Cervical cancer in the human papillomavirus vaccination era. Curr Opin Obstet Gynecol. 2012;24:3–7.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Eirini Taliouri
    • 1
  • Thomas Vrekoussis
    • 1
  • Aikaterini Vergetaki
    • 1
  • Theodore Agorastos
    • 2
  • Antonis Makrigiannakis
    • 1
  1. 1.Laboratory of Human Reproduction, Department of Obstetrics and Gynecology, Medical SchoolUniversity of CreteHeraklionGreece
  2. 2.4th Department of Obstetrics and Gynecology, Medical SchoolAristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations